EQS-Ad-hoc: CompuGroup Medical SE & Co. KGaA / Key word(s): Share Buyback The general partner of CompuGroup Medical SE & Co. KGaA (the “Company”) (ISIN: DE000A288904 | WKN: A28890), utilizing the authorization granted by its annual general meeting of May 19, 2021 pursuant to section 71(1) no. 8 of the German Stock Corporation Act (Aktiengesetz), resolved today to buy back a maximum number of up to 500,000 shares of the Company (corresponding to approx. 0.93% of the Company’s share capital) at a maximum aggregate purchase price (excluding transaction costs) of up to EUR 15,500,000 (the “Share Buy-Back Program”). The Share Buy-Back Program will be carried out by a credit institution. The credit institution will acquire the shares on the stock market and will decide on the timing of each acquisition independently of the Company in accordance with the safe harbor provisions of Article 5 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of April 16, 2014 (Market Abuse Regulation) in conjunction with the Commission Delegated Regulation (EU) 2016/1052 of March 8, 2016. In addition, the consideration paid per share (excluding transaction costs) must not exceed, or fall short of, the price of the Company’s shares in XETRA trading on the Frankfurt Stock Exchange determined by the opening auction on the trading day by more than 10%. Shares will be bought back in the period from March 26, 2024 to and including April 28, 2024. The Company’s treasury shares acquired by means of the Share Buy-Back Program may be used for any purpose permitted under the authorization granted by the annual general meeting of May 19, 2021. Further details will be published separately by the Company prior to the start of the share buy-back.
End of Inside Information
25-March-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Language: | English |
Company: | CompuGroup Medical SE & Co. KGaA |
Maria Trost 21 | |
56070 Koblenz | |
Germany | |
Phone: | +49 (0)160 3630362 |
Fax: | +49 (0)261 8000 3200 |
E-mail: | investor@cgm.com |
Internet: | www.cgm.com |
ISIN: | DE000A288904 |
WKN: | A28890 |
Indices: | SDAX, TecDAX |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: | 1866759 |
End of Announcement | EQS News Service |
|
1866759 25-March-2024 CET/CEST
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.